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Apart from the regular clinical trials, bioavailability/bioequivalence studies are conducted to assess the safety and 
efficacy of generic drugs, comparing it with a reference listed drug. Clinical trial data is mandatory for further approval of 
the drug, for it to enter the market. These investigations are strictly regulated by various global and national regulatory 
authorities. The global clinical trials market is expected to register a Compound Annual Growth Rate (CAGR) of nearly 
4.5% during the forecast period, 2018 to 2023. A major challenge for them to achieve the forecasted growth is meeting the 
increased level of compliance to the regulations. In recent times the research Organizations have been issued an increased 
number of warning letters with stringent procedures and even subsequent closure of the organizations. This case study 
conducted by the  review of warning letters and other observations pointed out by two major global regulatory authorities, 
the FDA and EMA and the critical areas were identified. Recommendations were made for the major areas which were 
critical and repetitive. It was concluded that consistent methods are required to improve the quality of studies to effectively 
eliminate the challenges in mere future and contribute for the betterment of the drugs’ market. 
Keywords: World Health Organization, Food and Drug Administration, Clinical Research Organizations, 
Quality Management System, clinical trials, regulatory authorities, warning letters, medical 
devices, drugs, biomedical research 
The concept of clinical trial is relatively recent 
which stemmed in part from the availability of more 
effective treatment modalities in recent years. The 
main stimulus arose from the recognition of the 
possibility that by chance a patient’s spontaneous 
improvement could coincide with the administration 
of the drug. Clinical trials are part of drug 
development aiming towards marketing authorization 
are designed logically and progressively with a 
continuous expanding process under controlled 
laboratory conditions. Such prospective biomedical or 
behavioral research studies on human participants are 
designed to answer specific questions about 
biomedical or behavioral interventions, including new 
treatments (such as, novel vaccines, drugs, dietary 
choices, dietary supplements, and medical devices) 
and known interventions that warrant further study 
and comparison. Clinical trials generate data 
on safety and efficacy. These are conducted only after 
the approval of health authority/ethics committee  in 
the country of the therapy (Table 1). The authorities 
are responsible for vetting the risk/benefit ratio of the 
trial.1-5 In the present scenario, pharmaceuticals are 
considered as the most highly regulated industries 
worldwide. The regulatory body ensures compliances 
in various legal and regulatory aspects of a drug. 
Every country has its own regulatory authority, which 
is responsible to enforce the rules and regulations and 
issue the guidelines to regulate drug development 
process, licensing, registration, manufacturing, 
marketing and labelling of pharmaceutical products.  
World Health Organization (WHO), Pan American 
Health Organization (PAHO), World Trade 
Organization (WTO), International Conference on 
Harmonization (ICH), World Intellectual Property 
Organization (WIPO) are some of the international 
regulatory agencies and organizations which  also 
play essential role in all aspects of pharmaceutical 
regulations  related to drug product registration, 
manufacturing, distribution, price control, marketing, 
research and development, and intellectual property 
protection.7 India had been a favourite destination for 
major pharmaceutical companies for conduct of 
clinical trials due to the advantage of large number of 
naive un-treated patients, which are difficult to find in 
developed countries. However, a common trend in the 
analytical and clinical trials sector is to compromise 
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quality for cost cutting and to meet timelines. There is 
a requirement for developing strategies to increase 
quality of study conduct in order for to produce 
studies with acceptable compliance to the regulatory 
requirements. 
Indian pharmaceutical industry is under increased 
scrutiny from the regulatory bodies especially FDA 
and WHO and the regulatory inspections had been 
intensified in recent times. The frequency of surprise 
audits had been increased marginally over the last few 
Table 1 — List of regulatory authorities6 
S. No Regulatory Authority 
1 USFDA- United States Food And Drug Administration (USA) 
2 MHRA- The Medicines and Health products Regulatory Agency (UK) 
3 TGA- Therapeutic Goods  Administration (Australia) 
4 CDSCO- The Central Drugs Standard Control Organization (India) 
5 HEALTH CANADA (Canada) 
6 MCC-Medicines Control Council (South Africa) 
7 ANVISA- National Health Surveillance Agency (Brazil) 
8 EMA- European Medicines Agency (European Union) 
9 SFDA- State Food and Drug Administration; replaced by the China Food and Drug Administration (China) 
10 NAFDAC- The National Agency for Food and Drug Administration and Control (Nigeria) 
11 MEDSAFE- Medicines and Medical Devices Safety Authority (New Zealand) 
12 MHLW- The Ministry of Health, Labour and Welfare (Japan) 
13 MCAZ- Medicines Control Authority of Zimbabwe 
14 SWISSMEDIC- The Swiss Surveillance Authority for Medicines and Medical Devices (Switzerland) 
15 KFDA- The Korea Food & Drug Administration, changed to  The Ministry of Food and Drug Safety (Korea) 
16 CDDA- Cosmetics, Devices and Drug Regulatory Authority (Sri Lanka) 
17 GCCDR- Gulf Central Committee for Drug Registration (Gulf countries) 
18 DGDA- Directorate General of Drug Administration (Bangladesh) 
19 DDA- Department of Drug Administration (Nepal) 
20 DRAP- Drug Regulatory Authority of Pakistan (Pakistan) 
21 DMA- Danish Medicines Agency (Denmark) 
22 AGES- Agency for Health and Food Safety (Austria) 
23 NIP- National Institute of Pharmacy (Hungary) 
24 Medicines Evaluation Board (Netherlands) 
25 Federal Agency for Medicines and Health Products (Belgium) 
26 National Institute of Health (Italy) 
27 Ministry of Health (Egypt, Iran, Israel, UAE, Jamaica, Botswana, Malaysia, Rwanda, Morocco, Swaziland, Ukraine, 
Slovenia, Cyprus, Luxembourg) 
28 TFDA- Tanzania Food and Drug Authority (Tanzania) 
29 National Drug Authority (Uganda) 
30 Health Sciences Authority (Singapore) 
31 DOH- Department of Health (Philippines) 
32 TFDA- Taiwan Food and Drug Administration (Taiwan) 
33 Department of Drug Administration (Nepal) 
34 POM- Pangawas Obut Dan Makanan (Indonesia) 
35 DRA- Drug Regulatory Authority (Bhutan) 
36 Ministry of Health and Population (Algeria) 
37 Pharmacy and Poisons Board (Kenya) 
38 Bulgarian Drug Agency (Bulgaria) 
39 National Medicines Agency (Romania) 
40 Norwegian Medicines Agency (Norway) 
41 The Office for Registration of Medicinal products, Medical Devices and Biocidal products (Poland) 
42 National Authority of Medicines and Health products (Portugal) 
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years. There were many instances of issuance of form 
483 and warning letters from FDA for serious 
violations of regulatory norms. A number of Indian 
CROs had been closed and some are on the verge of 
closing. Despite the challenges faced, international 
clinical trials remain critically important for global 
diseases that require international cooperation. 
International researchers and sponsors have to be 
aware of the regulatory requirements and expectations 
in the various countries in which they operate. Hence 
it is very important that the research centres and 
organizations conducting trials shall ensure that 
studies are conducted with high level quality which 
meets all the requirements of GCP and GLP. 
 
Basic Understanding of Regulations and Regulatory 
Bodies 
 
The Food and Drug Administration (FDA or USFDA)  
It is a federal agency of the United States 
Department of Health and Human Services, one of 
the United States Federal Executive Departments. The 
FDA is responsible for protecting and promoting 
public health through the regulations and supervision 
of food safety, tobacco products, dietary supplements,  
prescription and over-the-counter pharmaceutical 
drugs and vaccines, biopharmaceuticals, blood 
transfusion products, medical and electromagnetic 
devices, cosmetics, animal foods and feed and 
veterinary products. FDA periodically audits the 
laboratories which conduct studies in support of the 
marketing authorization requests. FDA identifies the 
lapses during the conduct of study and issues 
observations, listed in the form 483 in order of 
significance. The format for any single observation 
begins with a statement based in a citation of law, 
regulation or Act and is followed by a statement of 
specific conditions observed during the inspection. 
FDA’s Bio-research monitoring program is a 
comprehensive program of on-site inspections and 
data audits designed to monitor all aspects of the 
conduct and reporting of FDA-regulated research.2 
 
The European Medicines Agency (EMA)  
It is a decentralized agency of the European Union 
(EU), located in London. It began operating in 1995. 
The Agency is responsible for the scientific 
evaluation, supervision and safety monitoring of 
medicines developed by pharmaceutical companies 
for use in the EU. It protects public and animal health 
in 28 EU Member States, as well as the countries of 
the European Economic Area, by ensuring that all 
medicines available on the EU market are safe, 
effective and of high quality.1,6 
 
Good Clinical Practice (GCP)  
It is an international ethical and scientific quality 
standard for designing, conducting, recording and 
reporting trials that involve the participation of human 
subjects. Compliance with this standard provides 
public assurance that the rights, safety and well-being 
of trial subjects are protected; consistent with the 
principles that have their origin in the Declaration of 
Helsinki, and that the clinical trial data are credible.1, 3 
 
Good Laboratory Practices 
GLP is an FDA regulation which includes a set of 
principles which regulates planning, performance, 
monitoring, reporting and archival of the laboratory 
studies. The GLP includes use of calibrated 
instruments which is proven to be producing accurate, 
repeatable and reliable results, documentation 
practices which accurately reflects the original flow of 
events and results. Every activity shall be documented 
and the documentation practice as per GLP shall 
allow the exact reconstruction of events as it 
happened. The documents are required to be archived 
for a stipulated period of time and shall be made 
available for regulatory audits when requested. All the 
procedures in the laboratory shall be defined in 
standard operating procedures and shall be followed. 
A proper quality assurance unit should be  
functional in the laboratory independent of the 
analytical department.1 
 
The International Council on Harmonization (ICH)  
Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) is a project 
that brings together the regulatory authorities of 
Europe, Japan and the United States and experts from 
the pharmaceutical industry in the three regions to 
discuss scientific and technical aspects of 
pharmaceutical product registration. 
The purpose of ICH is to reduce or eliminate the 
need to duplicate the testing carried out during the 
research and development of new medicines by 
recommending ways to achieve greater harmonization 
in the interpretation and application of technical 
guidelines and requirements for product registration. 
Harmonization would lead to a more economical use 
of human, non-human animal and material resources, 
and the elimination of unnecessary delay in the global 
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development and availability of new medicines while 
maintaining safeguards on quality, safety, and 
efficacy, and regulatory obligations to protect  
public health.1 
 
Classification of Regulatory Observations 
World Health Organization (WHO) and ICH 
declared in the prequalification Inspection processes 
that non-compliance of Good Clinical Practices 
(GCP) as deficiencies might be due to the result of a 
defective procedures or failure to comply with the 
systems and procedures, problems due to lack of 
integrity, archiving and retrieval of documents, 
manual representation of peaks, data manipulation etc 
are few deficiencies. Thus, such deficiencies are 
classified as: critical observations, major observations 
and minor observations. 
 
Critical  
Conditions, practices or processes that adversely 
affect the rights, safety or wellbeing of the subjects 
and/or the quality and integrity of data which might 
cause potential risk to the user are considered as- 
Critical observations that are totally unacceptable. 
Observations classified as critical may include a 
pattern of deviations classified as major, bad quality 
of the data and/or absence of source documents. 
Manipulation and intentional misrepresentation of 
data belong to this group. Possible consequences 
include rejection of data and/or initiation of  
legal action. 
 
Major 
A non-critical observation that does not comply 
with specified guidelines having major deviation from 
GCP guidelines.  Observations classified as major, 
may include a pattern of deviations and/or numerous 
minor observations. Possible consequences include 
rejection of data and/or initiation of legal action. 
 
Minor 
Conditions, practices or processes that would not 
be expected to adversely affect the right, safety or 
well-being of the subjects and/or the quality and 
integrity of data. Possible consequences include the 
need for improvement of conditions, practices and 
processes. Many minor observations might indicate a 
bad quality and the sum might be equal to a major 
finding with its consequences. 
 
Methodology 
This Study was conducted to analyse various kinds 
of noncompliance as pointed out by two major 
regulatory bodies- FDA and EMA. Conclusions were 
drawn based on the commonly observed 
noncompliance across the laboratories and sites. 
Strategies to overcome the commonly observed 
deficiencies were prepared by keeping the guidelines 
provided by the regulatory authorities as the 
reference. The study includes- defining the objectives; 
data collection and analysis; identification of critical 
area and specific recommendations; summary and 
discussion; and conclusion. Major areas of critical 
findings were study monitoring, data management and 
clinical study reports. 
The study aimed to identify the lapses in systems 
followed by the sites and laboratories conducting 
clinical trials which result in regulatory queries 
regarding compliance to Good Laboratory Practices 
and Good Clinical Practices. It was also aimed to 
identify the possible reasons behind the 
noncompliance to the regulatory requirements and to 
suggest certain strategies to conduct clinical trials in 
effective compliance towards the GLP/GCP 
requirements. Basic concepts of regulations in clinical 
research are: 
a) Study various regulatory observations given 
to different companies 
b) Identify the lapses in systems followed by the 
laboratories and Contract Research Organizations 
c) Identification of reasons behind non-
compliance to regulatory requirements 
d) Conclude strategies to conduct clinical trials 
with effective compliance to regulatory requirements. 
Data was collected from warning letters and 
inspectional observations issued by FDA and EMA to 
various Clinical Research Organizations. The data 
was analysed thoroughly and the basic trends were 
identified and categorized into critical, major or minor 
observations according to the criticality and repetitive 
nature of the observations. 
 
FDA Findings from Bio - Research Monitoring Program 
Categories coming under FDA-BIMO Program  
are clinical investigators, Sponsor/monitor/CRO, 
bioequivalence/good laboratory practice, IRB 
(Institutional Review Board). BIMO inspections 
cover FDA-regulated products and conducted based 
on the FDA Compliance program guidance manual. 
Generally, inspections are carried out after the study 
is completed; however, FDA is contemplating to shift 
the inspection to ‘Real time’. The findings of FDA-
BIMO are classified as - No Action Indicated (NAI) - 
no objectionable conditions or practices were found 
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during the inspection and Voluntary Action Indicated 
(VAI) - objectionable conditions or practices were 
found during the inspection that represented 
departures from the regulations. VAI observations 
include- meeting minutes without sufficient details 
(attendance, actions); failure to maintain copies of all 
research proposals reviewed; failure to maintain list of 
IRB members; failure to follow written procedures; 
quorum related issues; subpart D related issues 
(usually not categorized); inappropriate use of 
expedited review; and failure to inform IRB of 
research approved by expedited review. Further, 
Official Action Indicated (OAI) – the objectionable 
conditions or practices found during the inspection 
represented significant departures from the 
regulations and may require the imposition of 
administrative/regulatory sanctions. OAI observations 
include- no written procedures; ICF consistently lacks 
required elements; continuing review dates 
consistently and substantially not met; consistently 
lack quorum; repeatedly allow conflicted IRB 
member to vote; repeatedly failed to maintain 
adequate records; substantially failed to minimize 
risk; failed to implement promised corrective actions; 
and behavior that results in referral to Office of 
Criminal Investigation (e.g. falsification of records). 
Statistical data of observations found as part of FDA-
BIMO program in 2015 is given in Table 2. The 
observations of FDA-BIMO during inspection in 
2015 are given in Fig. 1. Similarly, by analysing the 
data of regulatory audits conducted by EMA with 
respect to clinical trials from 2002-2012 (10 - year 
duration) the basic trends and common observations 
were identified (Fig. 2). 
 
Identification of Critical Area 
Observations related to IRB include-inadequate 
initial and /or continuing review; inadequate SOPs; 
inadequate membership rosters; inadequate meeting 
minutes; quorum issues; and inadequate 
communications with CI/institution. Observations 
related to CI include- clinical investigation is well 
organized and performed with a detailed study 
protocol where in many observations are considered 
as follows: 
 
Failure to Follow Investigational Plan 
a) Subjects enrollment without following 
inclusion/exclusion criteria like age, concomitant 
meds, history of systemic disorders and testing.  
b) Improper protocol design, employee training 
and supervision of employees  
c) Change of protocol during the study. The 
Principal Investigator (PI) can never change the 
protocol unless it is revised by the sponsor and 
approved by IRB. 
d) Failure to report serious adverse events 
(SAE) or Serious Adverse Device Effects (SADE) 
in accordance with the protocol.  As per 21CFR 
812.150 Unanticipated ADE must be reported to 
sponsor and IRB within 10 working days. 21CFR 
312.64(b) says, promptly report AE reasonably or 
probably caused by drug. If AE is alarming, report 
immediately. 
 
Table 2 — Statistical data of observations found as part of  
FDA-BIMO Program in 2015 
Category CI IRB Sponsor/monit
or/CRO 
BEQ GLP Total 
NAI 64% 59% 61% 67% 36% 63% 
VAI 33% 37% 31% 24% 56% 32% 
OAI 3% 4% 8% 9% 8% 5% 
 
 
 
Fig. 1 — The observations of FDA-BIMO during inspection in 2015. 
 
 
Fig. 2 — The observations of EMA during inspection in 2015 
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Protocol Deviations 
a) Improper, un-calibrated testing procedures 
during analysis of the samples. 
b) Follow up visits outside protocol window or 
incomplete (6 months contact by phone or visit).  
c) Improper documentation related to adverse 
events, blood data and other relevant data. 
d) Signed investigator statement without the list 
of co-investigators with significant responsibilities.  
e) Co-investigator enrolled subjects with 
exclusion criteria.  
f) No information of co-investigator’s training 
on research study. 
 
Inadequate Record Keeping 
a) No Source documentation to verify eligibility 
for a specific enrollment criterion. 
b) Study records show discrepancies between 
CRFs and source documents. 
c) CRFs can’t be verified by source documents 
and are not completed as source documents. 
 
Inadequate Accountability for Investigational Product 
a) Incomplete pharmacy records.   
b) Sponsor’s form is inadequate/ confusing details. 
 
Inadequate Communications with IRB 
a) Report not made to IRB for continuing review 
and approval lapsed. Subjects enrolled, devices 
implanted or study agents issued. 
 
Failure to Personally Conduct/ Adequately Supervise Trial 
a) Employee training and documentation. 
b) Screening and enrolling subjects. 
c) Informed consent issues. 
d) Lab results documentation. 
e) Follow-up evaluations done by staff members. 
 
Inadequate Subject Protection 
a) Inclusion criteria include– safety issues for 
subjects- enrollment of subject with exclusion criteria 
resulted in GI bleed requiring hospitalization. 
b) Protocol excludes device implant in subjects 
with arthritis in area. MRI showed exclusion criteria. 
Subject required revision surgery and device removal. 
c) Protocol deviations for safety testing in 
hematology/urinalysis pre/post treatment; lab  
work performed outside protocol window; and lab 
work missed. 
 
ICF Issues 
ICF issues include any of the 8 basic elements 
missing, i.e., statement of research: purpose, duration, 
procedures; foreseeable risks or discomforts; benefits 
that may reasonably be expected; alternative 
procedures; confidentiality and record review by 
FDA; compensation and injury treatment; contact for 
questions and injury report; and voluntary 
participation. Other ICF issues like, consent obtained 
prior to IRB approval; consent for wrong study was 
used to enrol; current IRB approved version not used; 
and consent form is dated by coordinator for 
the subject. 
 
Sponsor/Monitor/CRO Issues 
Inadequate monitoring; failure to bring 
investigators into compliance; inadequate 
accountability for the investigational product; and 
failure to obtain FDA and/or IRB approval prior to 
study initiation are few monitoring issues. Record 
keeping; inclusion/exclusion criteria issues; informed 
consent issues; dosage issues; analytical concerns- 
validation, stability; and inadequate SOPs are the 
issues related to bioequivalence.  Issues related to 
good laboratory practices, to name a few are- 
organizational and/or personnel inadequacies 
incomplete/inadequate/no study records; inadequate 
archiving; inadequate/no standard operating 
procedures (SOPs); and protocol deviations. 
 
Recommendations for Critical Areas 
Based on the study of various regulatory 
observations, critical areas were identified and 
specific recommendations are framed as follows: 
 
Quality Control Unit 
Failure of the quality control unit in ensuring 
quality outcome was found to be the major area of 
concern, as most of the regulatory observations were 
of simple nature, and could have been identified 
internally if a proper quality assurance system was in 
place. It was recommended that the internal quality 
assurance unit shall function independently and focus 
on regular monitoring. All the observations to be 
reported, corrective and preventive actions shall be 
ensured. Critical observations shall be made to the 
notice of the management also. 
 
Establish Written Procedures  
The insufficiency in written procedures such as, 
protocol, reports etc., is due to unawareness or 
negligence about the regulatory requirements. Most of 
the laboratories have written procedures and standard 
operating procedures in place for various activities. 
Laboratories need to ensure that all the activities are 
carried out based on written and approved procedures. 
This ensures that uniformity is maintained in various 
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lab activities irrespective of the personnel involved. It 
is also important to have proper training on standard 
operating procedures and continuous monitoring to 
ensure the compliance to the SOPs. 
 
Stability  
It is important to use any compound, stock 
solutions or dilutions within the established stability 
period. It is a common practice to use the compound 
beyond expiry and then prove stability later to cover 
the usage duration. However, this practice is not in 
compliance with the GLP requirements. Compounds 
for which the stability is proved and documented shall 
only be used for analytical research, as the results are 
greatly impacted due to the stability of stock and 
stock dilutions. Stability needs to be checked and 
documented under all conditions which the compound 
is expected to be associated with. 
 
Falsifying Test Data or Reporting Failed Results 
There were instances where the regulatory 
authorities were able to clearly establish that the data 
has been falsified. Most often, the discussions with 
the analysts in the laboratories reveal that the 
falsification of data is even with consent from the 
seniors at managerial level. This indicates serious 
noncompliance from the laboratory. Most often this is 
done to save time and management may not be aware 
of this practice. An independent Quality assurance 
system becomes most important here. The laboratory 
management shall ensure that trained personnel 
independent of the analytical department are 
monitoring the activities online. The QA shall directly 
report to the management and shall have the authority 
to stop activities if any falsification of data is found. 
Frequent review of audit trail entries is very 
important. Regulatory authorities expect the audit 
trails to be activated every time and available for 
reference at the time of inspection. All the data 
generated electronically need to meet the 
requirements as per the 21 CFR Part 11, which 
includes the requirement of audit trails. The analytical 
instrument needs to be configured in such a way that 
the audit trail is always enabled and cannot be 
disabled by the user. Quality Assurance unit shall 
ensure frequent review of audit trail and a proper back 
procedure for audit trail needs to be established. 
 
Adequate Controls to Prevent Manipulation and Omission of 
Data 
Data integrity and data safety are the most heard 
words recently associated with regulatory inspections. 
It is very clear from the recent increase in regulatory 
observations related to data safety and data integrity is 
the result of increase in focus of the regulatory bodies 
towards this. Many of the laboratories were lacking a 
proper system to ensure data integrity and data safety 
until recently. Observations made it clear that some of 
the laboratories still do not have proper system for 
controlled access to data. In some instances, analysts 
used administrator privileges even to the extent that 
analysts were able to change the date and time in the 
computer used with analytical instruments. Inspectors 
were able to provide proof for misuse of the 
administration rights. This shows complete failure of 
internal quality control systems. It needs to be ensured 
that every staff member has unique user name and 
password. Levels of access permissions need to be 
decided on the job functions of each staff and to be 
defined in a standard operating procedure. It is also 
important to conduct periodic checking on use of 
administrator rights. 
 
Investigation of Critical Deviations  
In most cases, the organizations try to hide the 
exact cause of failure or deviation fearing that 
revealing the exact reason will have a negative impact 
on the firm. But most often, it is easy for the auditors 
to find that actual reasons are not investigated 
perfectly. The organizations should take adequate care 
in investigating the failures and deviations completely 
to find out the root cause. Adequate measures shall be 
taken to establish corrective and preventive actions 
and recurrence shall be strictly avoided. If the auditor 
finds that proper investigation is being carried out for 
failures, which gives the confidence to auditor that the 
internal systems are working well and compliance  
is assured. 
 
Record Activities at the Time of Performance  
Online documentation is the most important 
compliance factor for a laboratory. As per the good 
laboratory practices, an activity should be 
logged/documented at the time of carrying out the 
activity. Even most sophisticated laboratories fail to 
comply 100% online documentation. There are 
several reasons for this including the negligence from 
the analysts. Another possibility is that some firms 
perform trial tests without documenting the procedure 
and if the test passes then they complete the 
documentation, which is not an acceptable practice as 
per the GLP standards. This practice is evident from 
other inspectional observations from FDA. Most of 
the miss matches in documentation happen due to the 
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practice of offline documentation. A proper quality 
assurance system is the only solution for this issue. 
QA should independently carry out in process audits 
for all the tests performed 
 
Governing the Functions and Operations of IRB 
Institutional review board or Internal Ethics 
committee plays a major role in assessing the study 
protocols and proposals. The ethics committee 
comprises people from various disciplines including a 
lay person. Responsibility and morale are expected 
from the ethics committee normally and it is the first 
independent check point for a study initiation. The 
regulatory expects all the meetings and discussions 
with IRB to be properly documented and the records 
are retained for inspection procedures. 
 
Backup system for Data  
In one of the audit observations, a computer system 
used for data collection in the organization, was 
crashed and there was no data available for 
inspection. Complete data was stored in the system 
and no back up was taken. This is a serious data 
safety issue and the regulatory bodies are more 
stringent about data integrity and data safety. Backup 
facility and other measure to store the data safely  
is mandatory. 
 
Audit Trail System for Electronically Generated Data 
Unauthorized analysis in the analytical system shall 
be prevented by enabling audit trail entry for 
electronically generated data. The audit trail shall be 
compared with the instrument log book in regular 
basis, and the backup of audit trail shall be taken. 
There were instances where auditors compared the 
instrument log with the electronic audit trail and 
found that there were unauthorized analyses 
conducted without recording in the log book. An SOP 
for audit trail management shall be in place and strict 
adherence to this SOP shall be ensured by the quality 
control unit. 
 
Administrative Privileges in Computers  
One of the observations read that ‘your quality 
control analysts used administrator privileges to 
change the controls for the time and date settings and 
manipulate file names to overwrite injections and 
delete original HPLC test data’. Analysts also 
routinely turned HPLC audit trails on and off. User 
levels the system shall be defined and different users 
shall log in with different user name and password. 
Only an IT administrator, who is independent of the 
laboratory activities, shall have administrative 
privileges for the computer systems. Frequent 
challenge tests shall be conducted to check if the  
user has options to change time or delete/modify  
the data. 
The study highlighted the importance of a proper 
Quality Management System in the laboratories/ 
organizations conducting clinical trials. The 
characteristics of a good Quality Management 
system include- standard operating procedures 
(SOPs) and continuous monitoring. SOPs are the 
most important part of any quality management 
system. SOP ensures that the procedure is done 
uniformly irrespective of the performer. It ensures 
quality and it reduces errors. As the SOPs are 
prepared after adequate review and discussions, it 
ensures quality in various angles. In addition to 
SOPs, specific protocols shall be prepared in a case 
to case basis. Procedure for review, approval, 
distribution and revision of SOPs shall be  
pre-defined. Continuous monitoring of all the 
activities is the key for success of any Quality 
Management System. Online and retrospective 
audits shall be conducted for every project. Audit 
observations shall be communicated and  
the compliance to be ensured. Review meetings 
shall be conducted frequently, which shall include 
user departments, Quality Assurance Team and 
management representative. 
 
Conclusion 
The study concluded that simple and strict steps 
taken to strengthen the internal quality management 
system can effectively contribute for the successful 
conductance of clinical trials in compliance to all 
the regulatory requirements. The challenges are 
complicated but can be met with simple 
improvement steps suggested by the regulatory 
bodies. The significant parameter in conducting the 
study is the time line along with the Quality. It is 
not required to follow different strategies for 
different regulatory bodies. A common strategy 
which focuses on internal Quality management 
system will help the organization to conduct studies 
with better compliance to the regulatory 
requirements. This will ensure faster growth of the 
clinical research industry, by gaining confidence 
from regulatory bodies. 
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